JP2007533722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533722A5 JP2007533722A5 JP2007508982A JP2007508982A JP2007533722A5 JP 2007533722 A5 JP2007533722 A5 JP 2007533722A5 JP 2007508982 A JP2007508982 A JP 2007508982A JP 2007508982 A JP2007508982 A JP 2007508982A JP 2007533722 A5 JP2007533722 A5 JP 2007533722A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- fluorothiazol
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 hydroxy, amino Chemical group 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 3
- 229940080818 propionamide Drugs 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 230000005494 condensation Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- HUUPNPWVDMNTAH-UHFFFAOYSA-N Nc1ncc(F)[s]1 Chemical compound Nc1ncc(F)[s]1 HUUPNPWVDMNTAH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56417104P | 2004-04-21 | 2004-04-21 | |
| US60107704P | 2004-08-12 | 2004-08-12 | |
| PCT/GB2005/050053 WO2005103021A1 (en) | 2004-04-21 | 2005-04-19 | Tri(cyclo) substituted amide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533722A JP2007533722A (ja) | 2007-11-22 |
| JP2007533722A5 true JP2007533722A5 (https=) | 2008-06-19 |
Family
ID=34965439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508982A Withdrawn JP2007533722A (ja) | 2004-04-21 | 2005-04-19 | トリ（シクロ）置換アミド化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080242869A1 (https=) |
| EP (1) | EP1740560A1 (https=) |
| JP (1) | JP2007533722A (https=) |
| KR (1) | KR20060134179A (https=) |
| AU (1) | AU2005235798A1 (https=) |
| BR (1) | BRPI0510163A (https=) |
| CA (1) | CA2563192A1 (https=) |
| EA (1) | EA012204B1 (https=) |
| IL (1) | IL178473A0 (https=) |
| MA (1) | MA28545B1 (https=) |
| MX (1) | MXPA06012008A (https=) |
| NO (1) | NO20065260L (https=) |
| NZ (1) | NZ550567A (https=) |
| WO (1) | WO2005103021A1 (https=) |
| ZA (1) | ZA200608489B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| BR0314864A (pt) | 2002-10-03 | 2005-08-02 | Novartis Ag | Compostos orgânicos |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| BRPI0509573A (pt) | 2004-04-02 | 2007-09-25 | Novartis Ag | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 |
| KR100890695B1 (ko) * | 2004-08-12 | 2009-03-26 | 프로시디온 리미티드 | 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도 |
| GB0418058D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
| KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| US20080293741A1 (en) * | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| KR20090025358A (ko) | 2006-07-24 | 2009-03-10 | 에프. 호프만-라 로슈 아게 | 글루코키나제 활성화제로서의 피라졸 |
| US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| JP5248477B2 (ja) * | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
| TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| JP5287730B2 (ja) | 2008-01-18 | 2013-09-11 | アステラス製薬株式会社 | フェニルアセトアミド誘導体 |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| KR101608259B1 (ko) | 2008-04-28 | 2016-04-01 | 교린 세이야꾸 가부시키 가이샤 | 시클로펜틸아크릴산아미드 유도체 |
| KR20110018366A (ko) | 2008-05-16 | 2011-02-23 | 다케다 샌디에고, 인코포레이티드 | 글루코키나아제 활성제 |
| CA2745843A1 (en) * | 2008-12-08 | 2010-06-17 | Hamid Hoveyda | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders |
| UA104742C2 (uk) | 2008-12-19 | 2014-03-11 | Эли Лилли Энд Компани | Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази |
| US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| US20130281708A1 (en) | 2010-03-18 | 2013-10-24 | Takeda California, Inc. | Process for the Production of 2-Amino-5-Fluorothiazole |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| PL350669A1 (en) * | 1999-03-29 | 2003-01-27 | Hoffmann La Roche | Glucokinase activators |
| US6353111B1 (en) * | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| DK1282611T3 (da) * | 2000-05-08 | 2005-02-14 | Hoffmann La Roche | Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer |
| DE60111534T2 (de) * | 2000-07-20 | 2006-05-11 | F. Hoffmann-La Roche Ag | Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren |
| DE60117059T2 (de) * | 2000-12-06 | 2006-10-26 | F. Hoffmann-La Roche Ag | Kondensierte heteroaromatische glucokinaseaktivatoren |
| EP1501815B1 (en) * | 2002-04-26 | 2006-11-22 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
-
2005
- 2005-04-19 MX MXPA06012008A patent/MXPA06012008A/es unknown
- 2005-04-19 JP JP2007508982A patent/JP2007533722A/ja not_active Withdrawn
- 2005-04-19 CA CA002563192A patent/CA2563192A1/en not_active Abandoned
- 2005-04-19 NZ NZ550567A patent/NZ550567A/en not_active IP Right Cessation
- 2005-04-19 EA EA200601747A patent/EA012204B1/ru not_active IP Right Cessation
- 2005-04-19 KR KR1020067022240A patent/KR20060134179A/ko not_active Ceased
- 2005-04-19 US US11/578,752 patent/US20080242869A1/en not_active Abandoned
- 2005-04-19 WO PCT/GB2005/050053 patent/WO2005103021A1/en not_active Ceased
- 2005-04-19 BR BRPI0510163-8A patent/BRPI0510163A/pt not_active IP Right Cessation
- 2005-04-19 EP EP05732317A patent/EP1740560A1/en not_active Withdrawn
- 2005-04-19 AU AU2005235798A patent/AU2005235798A1/en not_active Abandoned
-
2006
- 2006-10-05 IL IL178473A patent/IL178473A0/en unknown
- 2006-10-11 ZA ZA2006/08489A patent/ZA200608489B/en unknown
- 2006-10-20 MA MA29401A patent/MA28545B1/fr unknown
- 2006-11-15 NO NO20065260A patent/NO20065260L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533722A5 (https=) | ||
| JP2007508360A5 (https=) | ||
| KR101517064B1 (ko) | 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀 및 ｎｓａｉｄ를 포함하는 약제학적 병용제 | |
| JP2007508361A5 (https=) | ||
| JP2005501120A5 (https=) | ||
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| JP2008538741A (ja) | 鬱病の治療用及び／又は予防用の医薬組成物 | |
| JP2007519649A5 (https=) | ||
| JP2006501295A5 (https=) | ||
| JP2008521827A5 (https=) | ||
| JP2005523922A5 (https=) | ||
| JP2009504763A5 (https=) | ||
| JP2004512328A5 (https=) | ||
| JPH0920659A5 (https=) | ||
| WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
| JP2002513793A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| WO2006066896A3 (en) | Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin | |
| CA2530308A1 (en) | 5ht2c receptor agonists for the treatment of diabetes and obesity | |
| JP2009541387A5 (https=) | ||
| JP2005530852A5 (https=) | ||
| JP2019151627A5 (https=) | ||
| WO2006094763A8 (en) | 3,4,5-substituted piperidine compounds | |
| JP2004525178A5 (https=) | ||
| JP2009040767A5 (https=) |